Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development
Transformative closed-loop technology senses the spinal cord's response to stimulation and instantaneously adjusts therapy to sustain durable, optimized treatment
Using Orion, pharmaceutical and biotechnology companies, as well as any industrial researcher who wishes to perform electronic structure calculations, can gain access to elastic and flexible computational resources in the Cloud
Internationally accepted pharmaceutical GDP regulations stipulate that distributors of pharmaceutical products and warehouses must align their operations with the specified standards
It will be the first and only global office for traditional medicine in the world
Routine tests undertaken by women dropped by 35% in 2020
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Raising awareness about glaucoma is crucial in India where it is the leading cause of irreversible blindness with at least 12 million people affected and almost 1.2 million people blind from the disease
Subscribe To Our Newsletter & Stay Updated
